{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:25Z","timestamp":1790717005491,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118385","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:54:17Z","timestamp":1757508857000},"page":"118385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1 \u2013 An update (2020\u20132025)"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4871-0453","authenticated-orcid":false,"given":"Abanish","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesan","family":"Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118385_bb0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsbmb.2014.11.003","article-title":"Cytochrome P450 1 family and cancers","volume":"147","author":"Go","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"15","key":"10.1016\/j.bmc.2025.118385_bb0010","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","article-title":"Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development","volume":"15","author":"Bruno","year":"2007","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2012.04.021","article-title":"CYP1B1 and hormone-induced cancer","volume":"324","author":"Gajjar","year":"2012","journal-title":"Cancer Lett"},{"issue":"18","key":"10.1016\/j.bmc.2025.118385_bb0020","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1073\/pnas.93.18.9776","article-title":"17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1","volume":"93","author":"Hayes","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"10.1016\/j.bmc.2025.118385_bb0025","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2016.05.064","article-title":"Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1","volume":"26","author":"Lee","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"10.1016\/j.bmc.2025.118385_bb0030","doi-asserted-by":"crossref","first-page":"10937","DOI":"10.1073\/pnas.94.20.10937","article-title":"Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators","volume":"94","author":"Cavalieri","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.bmc.2025.118385_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1054\/bjoc.2001.1907","article-title":"Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer","volume":"85","author":"McFadyen","year":"2001","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2025.118385_bb0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0022-3565(24)38762-2","article-title":"Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?","volume":"296","author":"Rochat","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.bmc.2025.118385_bb0045","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1021\/acs.jmedchem.5b00265","article-title":"Design and synthesis of new \u0391-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression","volume":"58","author":"Cui","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.11.039","article-title":"Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1","volume":"163","author":"Mohd Siddique","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"21","key":"10.1016\/j.bmc.2025.118385_bb0055","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1016\/j.bmcl.2016.09.046","article-title":"Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives","volume":"26","author":"Poirier","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"10.1016\/j.bmc.2025.118385_bb0060","doi-asserted-by":"crossref","first-page":"9229","DOI":"10.1021\/acs.jmedchem.8b00907","article-title":"Targeting cytochrome P450 (CYP) 1B1 enzyme with four series of a-ring substituted estrane derivatives: design, synthesis, inhibitory activity, and selectivity","volume":"61","author":"Dutour","year":"2018","journal-title":"J Med Chem"},{"issue":"27","key":"10.1016\/j.bmc.2025.118385_bb0065","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1039\/C8RA00465J","article-title":"Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors","volume":"8","author":"Dong","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118385_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111938","article-title":"Synthesis and structure-activity relationship studies of \u03b1-naphthoflavone derivatives as CYP1B1 inhibitors","volume":"187","author":"Dong","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118385_bb0075","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1021\/acs.jmedchem.4c00164","article-title":"Design of novel 2-phenylquinazolin-4-amines as selective CYP1B1 inhibitors for overcoming paclitaxel resistance in A549 cells","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0080","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmech.2017.02.032","article-title":"Quinazoline derivatives as selective CYP1B1 inhibitors","volume":"130","author":"Mohd Siddique","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112895","article-title":"Discovery of heterocycle-containing \u03b1-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors","volume":"209","author":"Dong","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117944","article-title":"Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[h]chromen-4-one conjugates as dual ABCB1\/CYP1B1 inhibitors for overcoming MDR in cancer","volume":"114","author":"Dong","year":"2024","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118385_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bmc.2018.11.045","article-title":"Design and synthesis of selective CYP1B1 inhibitor via dearomatization of \u03b1-naphthoflavone","volume":"27","author":"Kubo","year":"2019","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2025.118385_bb0100","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1017\/S0007114512003595","article-title":"The citrus flavanone naringenin suppresses CYP1B1 transactivation through antagonising xenobiotic-responsive element binding","volume":"109","author":"Poon","year":"2013","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0300-483X(99)00215-2","article-title":"Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1","volume":"144","author":"Doostdar","year":"2000","journal-title":"Toxicology"},{"key":"10.1016\/j.bmc.2025.118385_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14786419.2024.2431996","article-title":"Design and synthesis of new alfa-naphthoflavanones as potent and selective CYP1B1 inhibitors","author":"Feng","year":"2024","journal-title":"Nat Prod Res"},{"key":"10.1016\/j.bmc.2025.118385_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129112","article-title":"A new class of CYP1B1 inhibitors derived from bentranil","volume":"80","author":"Yi","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118385_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118000","article-title":"Trans-Styrylquinazolinone CYP1B1 inhibitors as potential therapeutics in A549 cells","volume":"298","author":"Cai","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129776","article-title":"Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors","volume":"107","author":"Wei","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0130","doi-asserted-by":"crossref","first-page":"13978","DOI":"10.1038\/s41598-020-70597-8","article-title":"A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway","volume":"10","author":"Gilbert","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118385_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108786","article-title":"Discovery and synthesis of azepinoindoles as novel hCYP1B1 inhibitors with AhR-independent anticancer activity","volume":"163","author":"Wang","year":"2025","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cca.2005.05.002","article-title":"Modulation of Ah receptor and CYP1A1 expression by \u03b1-naphthoflavone in rainbow trout hepatocytes","volume":"141","author":"Aluru","year":"2005","journal-title":"Comp Biochem Physiol Part C Toxicol Pharmacol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1440-1681.13184","article-title":"Quinazolinone derivative BNUA-3 ameliorated [NDEA+2-AAF]-induced liver carcinogenesis in SD rats by modulating AhR-CYP1B1-Nrf2-Keap1 pathway","volume":"47","author":"Bose","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.bmc.2025.118385_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115552","article-title":"Discovery of 4\u2032-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation","volume":"258","author":"Wu","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118385_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01213011-200503000-00007","article-title":"Coumarins are competitive inhibitors of cytochrome P450 1B1, with equal potency for allelic variants","volume":"15","author":"Mammen","year":"2005","journal-title":"Pharmacogenet Genom"},{"issue":"12","key":"10.1016\/j.bmc.2025.118385_bb0160","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1007\/s00044-022-02962-3","article-title":"4-Phenylcoumarins from Mesua ferrea with selective CYP1B1 inhibitory activity","volume":"31","author":"Zhou","year":"2022","journal-title":"Med Chem Res"},{"issue":"9","key":"10.1016\/j.bmc.2025.118385_bb0165","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1039\/C9MD00258H","article-title":"Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents","volume":"10","author":"Dong","year":"2019","journal-title":"MedChemComm"},{"issue":"16","key":"10.1016\/j.bmc.2025.118385_bb0170","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.bmcl.2017.07.010","article-title":"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance","volume":"27","author":"Williams","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118385_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmech.2017.02.016","article-title":"Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: overcoming cisplatin resistance in CYP1B1-overexpressing lines","volume":"129","author":"Horley","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2022.108390","article-title":"In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: an integrated in vitro and ONIOM study","volume":"119","author":"Sharma","year":"2023","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.bmc.2025.118385_bb0185","first-page":"1","article-title":"Scaffold hopping for designing of potent and selective CYP1B1 inhibitors to overcome docetaxel resistance: synthesis and evaluation","author":"Raju","year":"2024","journal-title":"J Biomol Struct Dyn"},{"issue":"7","key":"10.1016\/j.bmc.2025.118385_bb0190","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.tiv.2015.06.014","article-title":"Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice","volume":"29","author":"He","year":"2015","journal-title":"Toxicol in Vitro"},{"issue":"26","key":"10.1016\/j.bmc.2025.118385_bb0195","doi-asserted-by":"crossref","first-page":"12339","DOI":"10.1039\/D3NJ01138K","article-title":"Identification of potential benzoxazolinones as CYP1B1 inhibitors via molecular docking, dynamics, waterswap, and in vitro analysis","volume":"47","author":"Raju","year":"2023","journal-title":"New J Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128570","article-title":"Diaryl triazenes inhibit cytochrome P450 1A1 and 1B1 more strongly than aryl morpholino triazenes","volume":"59","author":"Moran","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118385_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112235","article-title":"Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification","volume":"193","author":"Wang","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"24","key":"10.1016\/j.bmc.2025.118385_bb0210","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.1021\/acs.jmedchem.2c01306","article-title":"Structure-based drug design and synthesis of novel N-aryl-2,4-bithiazole-2-amine CYP1B1-selective inhibitors in overcoming taxol resistance in A549 cells","volume":"65","author":"Mao","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0215","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/acs.jmedchem.2c01368","article-title":"Design of cytochrome P450 1B1 inhibitors via a scaffold-hopping approach","volume":"66","author":"Hachey","year":"2023","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2025.118385_bb0220","doi-asserted-by":"crossref","first-page":"13089","DOI":"10.1021\/acs.jmedchem.5c01181","article-title":"Discovery of highly selective CYP1B1 inhibitors","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112028","article-title":"Design and synthesis of \u03b1-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation","volume":"189","author":"Zhou","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105295","article-title":"\u03b1-Naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: structure activity relationship","volume":"116","author":"Chen","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116488","article-title":"Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance","volume":"272","author":"Yao","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"23","key":"10.1016\/j.bmc.2025.118385_bb0240","doi-asserted-by":"crossref","first-page":"10901","DOI":"10.1021\/acs.jmedchem.8b01633","article-title":"Design, synthesis, and biological evaluation of cytochrome P450 1B1 targeted molecular imaging probes for colorectal tumor detection","volume":"61","author":"Meng","year":"2018","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.bmc.2025.118385_bb0245","doi-asserted-by":"crossref","first-page":"16032","DOI":"10.1021\/acs.jmedchem.3c01474","article-title":"Design and synthesis of novel near-infrared fluorescence probes based on an open conformation of a cytochrome P450 1B1 complex for molecular imaging of colorectal tumors","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118385_bb0250","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.4c01223","article-title":"Application of a CYP1B1-targeted NIR probe for breast cancer diagnosis, surgical navigation, and CYP1B1-associated chemotherapy resistance monitoring","author":"Wu","year":"2025","journal-title":"Mol Pharm"},{"issue":"14","key":"10.1016\/j.bmc.2025.118385_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200268","article-title":"Design, synthesis and in vivo fluorescence imaging study of a cytochrome P450 1B1 targeted NIR probe containing a chelator moiety","volume":"23","author":"Wang","year":"2022","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bmc.2025.118385_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129533","article-title":"Design, synthesis, and evaluation of 18F-labeling CYP1B1 PET tracer based on 2-phenylquinazolin","volume":"96","author":"Cai","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"issue":"36","key":"10.1016\/j.bmc.2025.118385_bb0265","doi-asserted-by":"crossref","first-page":"31999","DOI":"10.1021\/acsomega.2c02983","article-title":"Machine learning enabled structure-based drug repurposing approach to identify potential CYP1B1 inhibitors","volume":"7","author":"Raju","year":"2022","journal-title":"ACS Omega"},{"issue":"36","key":"10.1016\/j.bmc.2025.118385_bb0270","doi-asserted-by":"crossref","first-page":"20230","DOI":"10.1039\/D1CP02541D","article-title":"Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by \u03b1-naphthoflavone analogs","volume":"23","author":"Wang","year":"2021","journal-title":"Phys Chem Chem Phys"},{"issue":"11","key":"10.1016\/j.bmc.2025.118385_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2022.104204","article-title":"Methoxy and methylthio-substituted trans-stilbene derivatives as CYP1B1 inhibitors \u2013 QSAR study with detailed interpretation of molecular descriptors","volume":"15","author":"Pieku\u015b-S\u0142omka","year":"2022","journal-title":"Arab J Chem"},{"issue":"17","key":"10.1016\/j.bmc.2025.118385_bb0280","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1016\/j.bmc.2012.07.012","article-title":"Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1","volume":"20","author":"Mikstacka","year":"2012","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118385_bb0285","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1039\/c3md00317e","article-title":"3,4,2\u2032-Trimethoxy-trans-stilbene \u2013 a potent CYP1B1 inhibitor","volume":"5","author":"Mikstacka","year":"2014","journal-title":"MedChemComm"},{"issue":"6","key":"10.1016\/j.bmc.2025.118385_bb0290","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/cbdd.13042","article-title":"Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors","volume":"90","author":"Wierzchowski","year":"2017","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"10.1016\/j.bmc.2025.118385_bb0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/jm010298j","article-title":"Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors","volume":"45","author":"Kim","year":"2002","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118385_bb0300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1039\/c0md00242a","article-title":"Trans-stilbenoids: potent and selective inhibitors for human cytochrome P450 1B1","volume":"2","author":"Chun","year":"2011","journal-title":"MedChemComm"},{"issue":"3","key":"10.1016\/j.bmc.2025.118385_bb0305","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/ijms26031002","article-title":"Molecular docking study and 3D-QSAR model for trans-stilbene derivatives as ligands of CYP1B1","volume":"26","author":"Dutkiewicz","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:17:13Z","timestamp":1772878633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":61,"alternative-id":["S0968089625003268"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118385","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1 \u2013 An update (2020\u20132025)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118385"}}